SGN-LIV1A: Interim Phase I data

Interim data from 25 evaluable patients with previously treated LIV-1-positive metastatic breast cancer in an open-label, dose-escalation, U.S. Phase I trial showed that 0.5-2.8 mg/kg IV SGN-LIV1A eve...